Back to search results

Chemotherapy, Immunotherapy, and Motixafortide for Pancreatic Cancer

This study is testing a combination of treatments for metastatic pancreatic adenocarcinoma (a type of pancreatic cancer that has spread). You would receive standard chemotherapy (gemcitabine and nab-paclitaxel), along with cemiplimab (an immunotherapy that helps your immune system fight cancer cells) and motixafortide. Motixafortide is a new medication that laboratory studies suggest may help immunotherapy work better. The main goal is to see if this combination can shrink tumors. Researchers also want to understand if it can help people live longer and if it is safe. To join, you must have metastatic pancreatic adenocarcinoma confirmed by a doctor, and be at least 18 years old. The study plans to enroll 10 participants, but its current status is unclear.

Study design
This is a Phase 2, open-label study, meaning both you and the study team will know which treatments you are receiving. It plans to enroll 10 participants.
What's involved
You would receive motixafortide daily for 5 days, then twice weekly. Cemiplimab is given intravenously (into a vein) every 21 days, and gemcitabine and nab-paclitaxel are given intravenously on days 1, 8, and 14 of a 28-day cycle.
Compensation
Not stated in the trial record.
Follow-up
The study measures how well the treatment works (tumor shrinkage) at 16 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04543071

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Recruiting
PHASE2Ages 18+InterventionalTreatment
Gulam Manji
~10 participants
Updated 2025-06-19 on ClinicalTrials.gov
What's tested:MotixafortideCemiplimabGemcitabineNab paclitaxel

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Response Rate (Complete Response (CR) + Partial Response (PR))
Measured over 16 weeks

Conditions

Pancreatic Cancer
Adenocarcinoma of the Pancreas
Adenocarcinoma

Explore related trials

Pancreatic Carcinoma

Where it's being run

3 sites across 3 states
New York1
Rhode Island1
Wisconsin1

Study leadership

  • Gulam Manji, MD,PhD · PRINCIPAL_INVESTIGATOR · Columbia University

Who to contact

Research Nurse Navigator
[email protected]
212-342-5162
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Rash must cover \<10% of body surface area;
Disease is well-controlled at baseline and requires only low-potency topical corticosteroids;
No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months. 13. History of idiopathic pulmonary fibrosis, interstitial lung disease, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan (history of radiation pneumonitis or fibrosis in the radiation field is permitted). 14. Positive for HIV at screening or any time prior to screening Patients without prior positive HIV test result will undergo an HIV test at screening, unless not permitted under local regulations. 15. Hepatitis B virus (HBV) infection (chronic or acute) Defined as having a positive hepatitis B surface antigen (HBsAg) test at screening. Patients with a past or resolved HBV infection, defined as having a negative HBsAg test and a positive total hepatitis B core antibody test at screening, are eligible for the study. 16. Active hepatitis C virus (HCV) infection: Defined as positive HCV antibody test followed by a positive HCV RNA test at screening.

What this trial measures

  • Overall Response Rate (Complete Response (CR) + Partial Response (PR))16 weeks

    Complete response is defined as the disappearance of all lesions. Partial response is defined as ≥30% decrease in the sum of diameters of target lesions, in the absence of CR, new lesions, and unequivocal progression in non-target lesions.